Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Achieves Major Medicare Milestone for the Envisia Genomic Classifier
First Test for Improved IPF Diagnosis Receives Draft Local Coverage Determination Through the MolDx Program SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that it has received a draft Medicare local coverage determination (LCD) for the Envisia
View HTML
Toggle Summary Veracyte to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 p.m.
View HTML
Toggle Summary Veracyte Names Angeline McCabe as Vice President, Investor Relations and Corporate Communications
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 29, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has named Angeline (“Angie”) McCabe as vice president, investor relations and corporate communications, effective immediately. In this role, Ms.
View HTML
Toggle Summary Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m.
View HTML
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 5,750,000 shares of common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
View HTML
Toggle Summary Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 25, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $10.25 per share. The gross proceeds to Veracyte from this offering,
View HTML
Toggle Summary Veracyte Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 24, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
View HTML
Toggle Summary Veracyte Announces Second Quarter 2018 Financial Results
Revenue up 24% to $22.8 Million Compared to Second Quarter 2017 Increasing Revenue and Narrowing Cash Burn Guidance for Full-year 2018 Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 23, 2018-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018 . Following the announcement, Veracyte will host a conference call and webcast
View HTML
Toggle Summary Veracyte Chairman and CEO to Speak at MedCity CONVERGE
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 2, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie Anderson , chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers,
View HTML